Chris Rhodes

Chris Rhodes is a biopharmaceutical executive with more than 25 years of R&D leadership experience in pharmaceutical, biotechnology, delivery, and device companies.

He is a start-up specialist skilled at growing new technologies and translating research concepts into product development and commercialization.

Chris has been instrumental in the development of commercial products such as Byetta, Lusedra, Bydureon, Myalept, and Afrezza, with a focus on diabetes and metabolic diseases.

His expertise lies in biologics research, delivery system research, and development, with special emphasis on long-acting injectables and oral delivery technologies.

Specializing in long-acting injectables, oral delivery device and formulation technology, advanced delivery and device technology, polymers, conjugates, lipids, and nanotechnology, among others.

His specialties encompass various areas including drug development, diabetes, neuropathic pain, obesity, metabolic diseases, anesthesiology, ophthalmology, and technology assessment.

Chris Rhodes holds a post-doctoral degree from Yale University, a Ph.D. from the University of California, Los Angeles, and a B.S. from New York University.

He has held key positions such as President, CEO, and Founder at Drug Delivery Experts, Chief Technology Officer at Sensulin, LLC, and President at Christopher A Rhodes & Associates, to name a few.